respiratory

ERS 2017

Saturday 9th - Wednesday 13th September 2017
COPD

Mixed results for biologic in eosinophilic COPD

A subgroup of patients with COPD may benefit from biologic therapies, results of two Phase III trials suggest, but the jury is out on exactly which patients will benefit the most. The METREX trial, presented at ERS and published in the NEJM found 100...

A subgroup of patients with COPD may benefit from biologic therapies, results of two Phase III trials suggest, but the...
Asthma

Quadruple ICS reduces severe asthma exacerbations

A self managed four-fold increase in the dose of inhaled corticosteroids reduces severe asthma exacerbations, a late breaking trial at ERS Congress reports. According to the lead author Professor Tim Harrison, a respiratory physician from the University of Nottingham in the...

A self managed four-fold increase in the dose of inhaled corticosteroids reduces severe asthma exacerbations, a late breaking trial at...
Asthma

We need to radically rethink asthma: experts

Respiratory medicine experts have called for an overhaul of how asthma and other airways diseases are categorised and treated. Launching new recommendations in a specially commissioned article in The Lancet at the European Respiratory Society conference in Milan, Italy, the team of...

Respiratory medicine experts have called for an overhaul of how asthma and other airways diseases are categorised and treated. Launching ...